U.S. License Holder:
Date of License:
PEGASYS (peginterferon alfa-2a) is an antiviral indicated for:
Treatment of Chronic Hepatitis C (CHC) as part of a combination regimen with other hepatitis C virus (HCV) antiviral drugs in patients 5 years of age and older with compensated liver disease.
PEGASYS monotherapy is indicated for:
CHC only if patient has contraindication to or significant intolerance to other HCV antiviral drugs;
Treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation.